Tetra Bio Pharma Inc (OTCMKTS:TBPMF) Considering Lifesci Public Relations And Lifesci Advisors For Its Strategic Partners Positions

Tetra Bio Pharma Inc (OTCMKTS:TBPMF) has engaged investor relations firm LifeSci Advisors and a corporate communications firm LifeSci Public Relations. The business guru seeks to make these two of its strategic partners.

The engagement between the parties

LifeSci will pay focus to an investor relations and communications program and will see its proper implement ion nod execution. Under this will be the analyst and investor targeting/outreach, media engagement, and corporate communications. There will also be the non-deal roadshows, Key Opinion Leader (KOL), and social media events.

Tetra’s chief scientific officer who is also its chief executive officer Guy Chamberland says the engagement with LifeSci during is a good thing. Discussions are based on strategies that will help them spark about immense business growth.

The official also speaks about multiple value-creating milestones insisting there is much to do if they have to succeed. He is assertive on the need for them to communicate their overarching value proposition to investors in a clear way. The industry also needs to be aware of everything going on.

According to this official, nothing is as important to them as the achievement of these key inflection points.

Another official working with Tetra Bio Pharma in a recent interview said that everything with LifeSci Advisors commenced August 6, 2019. This engagement was held for over 12 months. LifeSci Advisors will have to be paid for the services it delivers. The total amount will add up to about US$30,000 per month. There will also be a 5% annual increase of the monthly fee as was disclosed by the company official.

A focus into the future

Tetra Bio Pharma says it will continue working closely with its subsidiaries. The business guru will pay more attention to subsidiaries developing Veterinary Products and Bio Pharmaceuticals containing cannabis. It also wants to ensure that all products under its name contain other medicinal plant-based elements.

Some of the parties set to benefit from the progressive moves by the company are physicians, regulators, and insurance companies. Tetra agrees that indeed serving healthcare providers and patients with novel treatments and drugs is a challenging affair. However, it confirms that it will be aggressive to ensure that nothing stops towards the provision of better healthcare services.


Tetra Bio Pharma Inc (OTCMKTS:TBPMF) Gets Shareholder Greenlight To Acquire Panag Pharma

Tetra Bio Pharma Inc (OTCMKTS:TBPMF) announced on Thursday last week during a special shareholder meeting that its shareholders approved plans to acquire Panag Pharma.

The company also revealed that the acquisition approval also includes a greenlight for acceleration events that were included in the management information circular that shareholders received prior to the meeting. Panag is a Canadian firm that develops innovative cannabinoid-based treatments for inflammation and pain. Both Panag and Tetra have teamed up to carry out various pre-clinical studies targeting inflammatory conditions and ophthalmic pain. The acquisition will thus allow Panag to add value to Tetra’s operations.

“We have been working with Panag for over a year and as a combined entity we will have a robust product pipeline of cannabinoid derived drugs for development as prescription or OTC drugs,” stated Tetra CEO, Dr. Guy Chamberland.

The proposed transaction is still subject to various conditions despite the approval by shareholders and this includes a pending TSXV approval. The transaction scheduled to be finalized before April 30 this month.

Tetra and Ovensa collaborate to fight brain cancer

Tetra previously announced that it partnered with Ovensa to tackle brain cancer cells and they plan to do that by delivering cannabinoids into brain cancer cells using the TRIOZAN nanomedicine platform. Dr. Chamberland pointed out that Glioblastoma multiforme (GBM) is one of the most common brain cancer types and worse still, it happens to be fatal. Some of the notable individuals that have succumbed to it include the musician Gordon Downey and Senator John McCain.

The Tetra CEO also revealed that there have previously been some studies that demonstrate cannabinoid activities on brain tumors. If the two companies achieve success through the technology, then there is a chance that they will boost the treatment’s efficacy allowing it to be used as a supplement to chemotherapy and radiotherapy.

Takeda Pharmaceutical Co Ltd (NYSE:TAK) and Ovensas also announced a collaboration aimed at evaluating the TRIOZANÔ technology’s ability to deliver an antibody to the brain. The partnership is also part of an active cancer research program. The technology is designed to facilitate a high level of engineering flexibility as far as nanomedicines are concerned.


Tetra Bio Pharma Inc (OTCMKTS:TBPMF) Advances Its European Drug Registration Plans

Tetra Bio Pharma Inc (OTCMKTS:TBPMF) has been working aggressively to accelerate its filing of a pre-marketing application for the enrolment of its cannabis drugs PPP005 and PPP001 under Directive-2001/83/EC of the European Parliament as well as of the Council. The company has completed numerous well-designed safety pharmacokinetic and pharmacodynamic trials in healthy subjects and has two current, well-designed clinical studies in patients. These studies are all double-blind, placebo controlled and randomized.

The upcoming plans

Tetra Bio Pharma reported that the Directive-2001/83/EC offers them with the regulatory and legal framework required for pre-marketing application filing of its cannabis drugs. Dr. Guy Chamberland, the Interim CEO and CSO, expressed that the company has conducted its own clinical studies and has impressive clinical study data to start the filing process for the registration of PPP005 and PPP001 under the Directive 2001/83/EC.

They plan to get a Full Market Authorisation since Tetra has a report supporting the therapeutic product’s safety, efficacy and quality. Tetra has performed all its clinical studies with the quality of evidence as mandated by the National Competent authorities approving drugs.

Earlier in this month, Tetra Bio-Pharma secured a CBD supply deal with True North Cannabis in Canada. The former firm will advance a cannabinoid derived topical cream and oral capsule for curing joint pain and inflammation. These products are expected to be commercialized under the earlier reported association with Genacol. As per the industry report, the industry of topical pain relief products is valued at over $2.5 billion. The new offerings are expected to be released in 2019.

Tetra Bio Pharma’s formulation and regulatory expertise along with clinical study data from its PPP005 studies will go a long way to advance these unique offerings for Genacol. It will work with the regulatory agencies to get marketing authority within Genacol’s global sales network where their brand offerings are available in over 40 nations, including Europe, Asia, Latin America, the Middle East, Africa and the U.S.


Tetra Bio Pharma Inc (OTCMKTS:TBPMF) Partners With Genacol Canada Corporation To Offer Cannabinoid Treatments To Self-Care Market In Canada

Tetra Bio Pharma Inc (OTCMKTS:TBPMF) and Genacol Canada Corporation have signed a Development and Commercialization agreement. Tetra Bio Pharma is one of the leading cannabis companies specializing in the discovery as well as development of drugs.

Terms of the agreement

Under the agreement, Tetra Bio-Pharma will be in charge of the development and production of a cannabinoid extracted from oral capsule. The company will also produce a topical cream to be used in treating inflammation and joint pain.

On the other hand, Genacol will be in charge of marketing the product and will seek to cover the whole of Canada. Statistics in the industry have shown that the market for relief products used to reduced pain is over $2.5 billion. According to a statement from the two companies, the products will be on the market in 2019.

Tetra Bio-Pharma is banking on its long expertise in the industry plus a databank of information from its clinical trials to produce high quality products for Genacol. In a statement, Tetra Bio-Pharma interim CEO and Chief Scientific Officer Guy Chamberland said it is a big milestone for his company to work with Genacol, a leader in Canada’s cannabis sector. He added that Genacol has a big sales network, which will ensure that the products get enough exposure.

Tetra Bio-Pharma to conduct a clinical trial on PPP001 drug

In other news, Tetra Bio-Pharma has secured an approval from Health Canada to conduct a clinical trial on its PPP001 drug. The drug is being developed as an alternative to opioid fentanyl in reducing cancer pain. The clinical study will be done by Montreal-based Santé Cannabis contract research organization and medical clinic, which mainly focuses on clinical research in the cannabis sector.

The study will seek to determine pain relief products in patients having cancer pains. According to data from previous clinical studies, the company is convinced that PPP001 may be used to develop a novel alternative to opioid fentanyl. This is because of the pharmacodynamic properties of PPP001. In addition, PPP001 is known to have the right time-to-maximal plasma concentrations of THC hence it is effective in pain relief.


Tetra Bio Pharma Inc (OTCMKTS:TBPMF) Adds Extension To North Bud Farms Inc; Gets Approval From Health Canada For PPP001 Drug

Tetra Bio Pharma Inc (OTCMKTS:TBPMF) recently announced that it is extending North Bud Farms Inc. These two companies are working together for finalizing a transaction. At its end, Tetra BioPharma has decided to extend its agreement with North Bud Farms so that the latter can get enough time to come up with the final receipt of its prospectus.

Tetra waiting for North Bud to provide final receipt of prospect

One of the important conditions of the sale is that the relevant documents will have to be submitted by the end of this month. Tetra can declare record data and start distributing dividend only after it receives a final receipt of the prospectus of North Bud Farms and fulfills the requirements as deemed mandatory by the Ontario Securities Commission. Tetra will have to announce the record date and start dividend distribution before finalizing shares listing of North Bud Farms Inc.

Tetra Bio Pharma receives approval from Health Canada

Tetra Bio-Pharma is a leading company in biopharmaceutical field with an approval from Health Canada for carrying out research to discover and develop the cannabinoid-based drug. The research programs from Tetra are reviewed by FDA and its clinical program brings novel prescription treatments and drugs to patients as well as to healthcare providers. Apart from the contribution from Tetra as a company, its subsidiaries too contribute in developing an advanced pipeline of Natural Health, Pharmaceuticals, and Veterinary Products that contain medicinal plant and cannabis as a primary element.

Recently the company declared that Health Canada has given approval to its clinical trial currently investigating PP001 drug as an option to opioid fentanyl. This particular drug is used for managing cancer pain. Sante Cannabis, based in Montreal is a contract research organization and medical clinic that is conducting this clinical trial. The organization is specialized in conducting clinical research for marijuana and related therapies.

 As per the report, the clinical trial is being carried out for assessing the time of relief patients suffering from breakthrough cancer pain will get. The company is of the opinion that the pharmacodynamic properties present in PPP001 may act faster and as a better alternative to opioid fentanyl.

Pin It on Pinterest